KR20240118832A - 폴리펩티드 조절제 - Google Patents

폴리펩티드 조절제 Download PDF

Info

Publication number
KR20240118832A
KR20240118832A KR1020247022359A KR20247022359A KR20240118832A KR 20240118832 A KR20240118832 A KR 20240118832A KR 1020247022359 A KR1020247022359 A KR 1020247022359A KR 20247022359 A KR20247022359 A KR 20247022359A KR 20240118832 A KR20240118832 A KR 20240118832A
Authority
KR
South Korea
Prior art keywords
disease
syndrome
polypeptide
cancer
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022359A
Other languages
English (en)
Korean (ko)
Inventor
사미르 클레이프
미카엘 믹르티치얀
Original Assignee
조지아뮨 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조지아뮨 인코포레이티드 filed Critical 조지아뮨 인코포레이티드
Publication of KR20240118832A publication Critical patent/KR20240118832A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020247022359A 2021-12-10 2022-12-08 폴리펩티드 조절제 Pending KR20240118832A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288330P 2021-12-10 2021-12-10
US63/288,330 2021-12-10
PCT/US2022/081186 WO2023108073A2 (en) 2021-12-10 2022-12-08 Polypeptide modulators

Publications (1)

Publication Number Publication Date
KR20240118832A true KR20240118832A (ko) 2024-08-05

Family

ID=86731448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022359A Pending KR20240118832A (ko) 2021-12-10 2022-12-08 폴리펩티드 조절제

Country Status (10)

Country Link
US (1) US20250051419A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444339A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546654A (cg-RX-API-DMAC7.html)
KR (1) KR20240118832A (cg-RX-API-DMAC7.html)
CN (1) CN118613277A (cg-RX-API-DMAC7.html)
AU (1) AU2022405109A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241913A1 (cg-RX-API-DMAC7.html)
IL (1) IL313360A (cg-RX-API-DMAC7.html)
MX (1) MX2024006897A (cg-RX-API-DMAC7.html)
WO (1) WO2023108073A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026519808A (ja) * 2023-06-06 2026-06-18 ジョージアミューン・インコーポレイテッド 新規pd-l2変異体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000692A2 (en) * 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN106794235A (zh) * 2014-07-18 2017-05-31 阿德瓦希斯公司 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
US11219694B2 (en) * 2015-09-24 2022-01-11 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
JP2020511144A (ja) * 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
WO2019060888A1 (en) * 2017-09-25 2019-03-28 New York University HETÉRODIMÈRE-FC FUSION PROTEINS
US20210213063A1 (en) * 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3908600A1 (en) * 2019-01-11 2021-11-17 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Fusion protein with immunosuppressive activity

Also Published As

Publication number Publication date
JP2024546654A (ja) 2024-12-26
WO2023108073A3 (en) 2023-10-19
CN118613277A (zh) 2024-09-06
EP4444339A2 (en) 2024-10-16
CA3241913A1 (en) 2023-06-15
MX2024006897A (es) 2024-06-20
AU2022405109A1 (en) 2024-06-27
US20250051419A1 (en) 2025-02-13
WO2023108073A2 (en) 2023-06-15
IL313360A (en) 2024-08-01
EP4444339A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
JP7630426B2 (ja) ヘテロ二量体fc融合タンパク質
JP7461350B2 (ja) Arg1及び/又はarg2の阻害剤
ES2759075T3 (es) Un anticuerpo monoclonal y un método del mismo
KR20230146528A (ko) 암을 치료하기 위한 방법
TWI812918B (zh) IL-7Rαγc結合化合物
CA3169523A1 (en) Transglutaminase-mediated conjugation
JP7863349B2 (ja) ガンマデルタt細胞を刺激するための方法及び組成物
EP3583113B1 (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
US20160304579A1 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
CN102203132A (zh) Pd-1拮抗剂的组合物和使用方法
TW202132332A (zh) IL—2Rβγc結合化合物
CA3127459A1 (en) Compositions and methods for stimulating natural killer cells
WO2016115218A1 (en) Antibody drug conjugates for the treatment of immune conditions
US20250051419A1 (en) Polypeptide modulators
KR20260021697A (ko) 신규한 pd-l2 돌연변이체
HK40114371A (en) Polypeptide modulators
RU2792239C2 (ru) Химерные белки на основе csf1r
WO2025133213A1 (en) Death receptor 5 (dr5)-armored car-t therapeutic
TW202528536A (zh) IL—2Rβγ促效劑肽在細胞製造中之用途
WO2023083439A1 (en) Tlr7 agonist and combinations for cancer treatment
HK40021169B (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
HK40021169A (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000